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Abstract
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of EFSA was
requested to evaluate three ﬂavouring substances, 2,5-dimethyl-4-ethoxyfuran-3(2H)-one [FL-no:
13.117], 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] and 4-Acetyl-2,5-dimethylfuran-3(2H)-one
[FL-no: 13.175] in the Flavouring Group Evaluation 313 (FGE.313), using the Procedure in Commission
Regulation (EC) No 1565/2000. The substances were considered in FGE.220, and revisions hereof, not
to have genotoxic potential. They were evaluated through a stepwise approach that integrates
information on the structure–activity relationships, intake from current uses, toxicological threshold of
concern, and available data on metabolism and toxicity. The Panel concluded that the two ﬂavouring
substances [FL-no: 13.117, 13.119] do not give rise to safety concerns at their level of dietary intake,
estimated on the basis of the Maximised Survey-derived Daily Intake (MSDI) approach. For the
ﬂavouring substance [FL-no: 13.175], toxicity data are required. Besides the safety assessment of the
ﬂavouring substance, the speciﬁcations for the materials of commerce have also been considered.
Adequate speciﬁcations including complete purity criteria and identity for the materials of commerce
have been provided for the three ﬂavouring substances. The Panel concluded that for 2,5-dimethyl-4-
ethoxyfuran-3(2H)-one [FL-no: 13.117], 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] and 4-acetyl-2,5-
dimethylfuran-3(2H)-one [FL-no: 13.175] for which the Modiﬁed Theoretical Added Maximum Daily
Intakes (mTAMDIs) are above the thresholds for their structural class, more reliable exposure data are
required for a re-evaluation.
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Summary
Following a request from the European Commission, the European Food Safety Authority (EFSA)
Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to
deliver a scientiﬁc opinion on the implications for human health of chemically deﬁned ﬂavouring
substances used in or on foodstuffs in the Member States. In particular, the Panel was requested to
evaluate three ﬂavouring substances in the Flavouring Group Evaluation 313 (FGE.313), using the
Procedure referred to in Commission Regulation (EC) No 1565/2000 ‘(hereinafter “the Procedure”)’.
These ﬂavouring substances belong to chemical group 13 of Annex I of the Commission Regulation
(EC) No 1565/2000.
The three candidate substances under evaluation are a,b-unsaturated 3(2H)-furanone derivatives
from chemical group 13: 2,5-dimethyl-4-ethoxyfuran-3(2H)-one [FL-no: 13.117], 2,5-dimethylfuran-
3(2H)-one [FL-no: 13.119] and 4-Acetyl-2,5-dimethylfuran-3(2H)-one [FL-no: 13.175].
All three substances possess one chiral centre and their stereoisomeric composition has been
speciﬁed.
The three candidate substances were assigned to structural class III, according to the decision tree
approach presented by Cramer et al., 1978.
[FL-no: 13.117 and 13.119] have been reported to occur naturally in food.
In its evaluation, the Panel, as a default, used the ‘Maximised Survey-derived Daily Intake’ (MSDI)
approach to estimate the per capita intakes of the ﬂavouring substances in Europe. However, when
the Panel examined the information provided by the European Flavouring Industry on the use levels in
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly
underestimate the intake by regular consumers of products ﬂavoured at the use level reported by the
Industry, especially in those cases where the annual production values were reported to be small. In
consequence, the Panel had reservations about the data on use and use levels provided and the intake
estimates obtained by the MSDI approach.
In the absence of more precise information that would enable the Panel to make a more realistic
estimate of the intakes of the ﬂavouring substances, the Panel has decided also to perform an
estimate of the daily intakes per person using a ‘modiﬁed Theoretical Added Maximum Daily Intake’
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the
mTAMDI approach indicated that the intake of a ﬂavouring substance might exceed its corresponding
threshold of concern, the Panel decided not to carry out a formal safety assessment using the
Procedure. In these cases, the Panel requires more precise data on use and use levels.
According to the default MSDI approach, the candidate substances in this group have intakes in
Europe from 0.018 to 1.7 lg/capita per day. For all the candidate substances, this is below the
threshold of concern value for structural class III (90 lg/person per day). On the basis of the reported
annual production volumes in Europe (EFFA, 2004b), the estimated combined daily per capita intake as
ﬂavourings of the three candidate substances assigned to structural class III is approximately 3 lg,
which does not exceed the threshold of concern for a compound belonging to structural class III of
90 lg/person per day.
The Panel concluded that the two candidate substances for which genotoxicity data were submitted
(2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] and 4-acetyl-2,5-dimethylfuran-3(2H)-one [FL-no:
13.175]) do not give rise to concern with respect to genotoxicity. The same conclusion applies to 2,5-
dimethyl-4-ethoxyfuran-3(2H)-one [FL-no: 13.117], which is structurally related with respect to the
a,b-unsaturated carbonyl moiety. Therefore, these three substances can be evaluated using the
Procedure.
The candidate substance [FL-no: 13.117] is expected to be metabolised to innocuous products.
Therefore, [FL-no: 13.117] was evaluated via the A-side of the Procedure. [FL-no: 13.119 and 13.175]
cannot be anticipated to be metabolised to innocuous products. Consequently, these two substances
were evaluated via the B-side of the Procedure.
It is considered that the two candidate substances 2,5-dimethyl-4-ethoxyfuran-3(2H)-one [FL-no:
13.117] and 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] evaluated through the Procedure would not
give rise to safety concerns at the estimated levels of intake arising from their use as ﬂavouring
substances on the basis of the default MSDI approach. Additional toxicity data are required for
4-acetyl-2,5-dimethylfuran-3(2H)-one [FL-no: 13.175].
In order to determine whether the conclusion for the candidate substances can be applied to the
materials of commerce, it is necessary to consider the available speciﬁcations.
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Adequate speciﬁcations including complete purity criteria and identity for the material of commerce
have been provided for the ﬂavouring substances.
The estimated intake based on the mTAMDI approach is 1,000 lg/person per day for each of the
candidate substances from structural class III, which is above the threshold of concern for structural
class III of 90 lg/person per day. The Panel concluded that for 2,5-dimethyl-4-ethoxyfuran-3(2H)-one
[FL-no: 13.117], 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] and 4-acetyl-2,5-dimethylfuran-3(2H)-
one [FL-no: 13.175] for which the mTAMDIs are above the thresholds for their structural class, more
reliable exposure data are required. On the basis of such additional data, these ﬂavouring substances
should be reconsidered using the Procedure. Subsequently, additional toxicity data might become
necessary. For the candidate substance [FL-no: 13.175], toxicity data are required.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The use of ﬂavourings is regulated under Regulation (EC) No 1334/2008 of the European
Parliament and Council of 16 December 20081 on ﬂavourings and certain food ingredients with
ﬂavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for ﬂavouring substances.
The Union list of ﬂavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20122. The list contains ﬂavouring substances for which the scientiﬁc
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20003.
The European Food Safety Authority (EFSA) concluded that a genotoxic potential of ﬁve 3(2H)-
furanones, corresponding to subgroup 4.4a of Flavouring Group Evaluation 19 (FGE.19) in
FGE.220Rev1, could not be ruled out.
Information on two representative materials has now been submitted by the European Flavour
Association. These are 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] and 4-acetyl-2,5-dimethylfuran-3
(2H)-one [FL-no: 13.175]. This information is intended to cover the re-evaluation of these two
substances and of two substances from FGE.19 subgroup 4.4a: 2,5-dimethyl-4-methoxyfuran-3(2H)-
one [FL-no: 13.089] and 2,5-dimethyl-4-ethoxyfuran-3(2H)-one [FL-no: 13.117].
1.1.1. Terms of Reference as provided by the European Commission
The European Commission requests EFSA to evaluate this new information and, depending on the
outcome, proceed to the full evaluation on these ﬂavouring substances in accordance with Commission
Regulation (EC) No 1565/2000.
1.2. Interpretation of the Terms of Reference
The present scientiﬁc opinion FGE.313 covers the safety assessment of two a,b-unsaturated 3(2H)-
furanone derivatives from chemical group 13: the 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] and
2,5-dimethyl-4-ethoxyfuran-3(2H)-one [FL-no: 13.117].
2. Assessment
2.1. Presentation of the substances in Flavouring Group Evaluation 313
2.1.1. Description
The present FGE.313, using the Procedure as referred to in the Commission Regulation (EC)
No 1565/2000 (the Procedure – shown in schematic form in Appendix B of this FGE), deals with three
ﬂavouring substances (candidate substances) from chemical group 13 of Annex I of Commission
Regulation (EC) No 1565/20003.
The candidate substances under consideration in the present evaluation, with their chemical
Register name, FLAVIS- (FL-), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor
and Extract Manufacturers Association (FEMA) numbers, and structures are listed in Table 1.
The outcome of the safety evaluation is summarised in Table A.1.
1 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on ﬂavourings and certain
food ingredients with ﬂavouring properties for use in and on foods and amending Council Regulation (EEC) No 1601/91,
Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34–50.
2 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of ﬂavouring substances provided
for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to Regulation (EC)
No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) No 1565/2000 and
Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1–161.
3 Commission Regulation (EC) No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8–16.
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All three candidate substances are a,b-unsaturated 3(2H)-furanones allocated to FGE.220 or the
following revisions. In FGE.220Rev2 (EFSA CEF Panel, 2013), one of the candidate substances, 2,5-
dimethylfuran-3(2H)-one [FL-no: 13.119] was evaluated and it was considered not to be of concern
with respect to genotoxicity. The two other candidate substances were considered not to be of
concern with respect to genotoxicity based on new data considered in FGE.220Rev3 (EFSA CEF Panel,
2015a). The candidate substances in this FGE are structurally related to furanone derivatives which
have previously been considered by EFSA in FGE.99 and FGE.99Rev1 (EFSA CEF Panel, 2015b).
2.1.2. Stereoisomers
It is recognised that geometrical and optical isomers of substances may have different properties.
Their ﬂavour may be different; they may have different chemical properties resulting in possible
variability in their absorption, distribution, metabolism, elimination and toxicity. Thus, information must
be provided on the conﬁguration of the ﬂavouring substance, i.e. whether it is one of the geometrical/
optical isomers, or a deﬁned mixture of stereoisomers. The available speciﬁcations of purity will be
considered in order to determine whether the safety evaluation carried out for candidate substances
for which stereoisomers may exist can be applied to the material of commerce. Flavouring substances
with different conﬁgurations should have individual chemical names and codes (CAS number, FLAVIS
number, etc.).
All three candidate substances, possess one chiral centre and the stereoisomeric composition has
been speciﬁed (EFFA, 2013, 2015) (see Table 1).
2.1.3. Natural occurrence in food
According to TNO (TNO, 2015), two of the three candidate substances have been reported to occur
in coffee, guava, mango, passion fruit, wheaten bread and wild rice. Quantitative data on the natural
occurrence in food have been reported for both of these substances (see Table 2).
4-Acetyl-2,5-dimethylfuran-3(2H)-one [FL-no: 13.175] has not been reported to occur naturally in
food (TNO, 2015).
Table 1: Speciﬁcation summary of the substances in the Flavouring Group Evaluation 313
FL-no
JECFA-no
EU Register
name
Structural
formula
FEMA no
CoE no
CAS no
Phys. form
Mol. formula
Mol. weight
Solubility(a)
Solubility in
ethanol(b)
Boiling point, °C(c)
Melting point, °C
ID test
Assay minimum
Refrac.
index(d)
Spec.
gravity(e)
Speciﬁcation
comments
13.117 2,5-Dimethyl-4-
ethoxyfuran-
3(2H)-one 65330-49-6
Solid
C8H12O3
156.18
Practically
insoluble or
insoluble
Freely soluble
251
60
MS
95%
n.a.
n.a.
Racemate
(EFFA, 2015)
13.119 2,5-
Dimethylfuran-
3(2H)-one
11066
14400-67-0
Liquid
C6H8O2
112.13
Practically
insoluble
Freely soluble
68 (16 hPa)
IR NMR MS
95%
1.473–1.479
1.050–1.060
Racemate
(EFFA, 2013)
13.175 4-Acetyl-2,5-
dimethylfuran-
3(2H)-one
Solid
C8H10O3
154.17
Very slightly
soluble
Freely soluble
283
34
NMR MS
95%
n.a.
n.a.
Racemate
(EFFA, 2015).
CASrn 36871-
78-0 to be
introduced in
the Register
FL-no: FLAVIS-number; JECFA-no: The Joint FAO/WHO Expert Committee on Food Additives number; EU: European Union; FEMA no: Flavor and Extract
Manufacturers Association number; CoE no: Council of Europe number; CAS no: Chemical Abstract Service number; ID: identity; MS: mass spectrometry;
IR: infrared spectroscopy; NMR: nuclear magnetic resonance.
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95% ethanol, if not otherwise stated.
(c): At 1,013.25 hPa (1 atm), if not otherwise stated.
(d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.
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2.2. Speciﬁcations
Purity criteria for the candidate substance have been provided by the Flavour Industry (EFFA, 2015)
(Table 1).
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/20003, this
information is adequate for the candidate substances (see Section 2.1.2 and Table 1).
2.3. Intake data
Annual production volumes of the ﬂavouring substances as surveyed by the Industry can be used
to calculate the ‘Maximised Survey-derived Daily Intake’ (MSDI) by assuming that the production ﬁgure
only represents 60% of the use in food due to underreporting and that 10% of the total EU population
are consumers (SCF, 1999).
However, the Panel noted that due to year-to-year variability in production volumes, to
uncertainties in the underreporting correction factor and to uncertainties in the percentage of
consumers, the reliability of intake estimates on the basis of the MSDI approach is difﬁcult to assess.
The Panel also noted that in contrast to the generally low per capita intake ﬁgures estimated on the
basis of this MSDI approach, in some cases, the regular consumption of products ﬂavoured at use
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In such
cases, the human exposure thresholds below which exposures are not considered to present a safety
concern might be exceeded.
Considering that the MSDI model may underestimate the intake of ﬂavouring substances by certain
groups of consumers, the Scientiﬁc Committee on Food (SCF) recommended also taking into account
the results of other intake assessments (SCF, 1999).
One of the alternatives is the ‘Theoretical Added Maximum Daily Intake’ (TAMDI) approach, which
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for ﬂavoured
beverages and foods in general, with exceptional levels for particular foods. This method is regarded
as a conservative estimate of the actual intake by most consumers because it is based on the
assumption that the consumer regularly eats and drinks several food products containing the same
ﬂavouring substance at the upper use level.
One option to modify the TAMDI approach is to base the calculation on normal rather than upper
use levels of the ﬂavouring substances. This modiﬁed approach is less conservative (e.g. it may
underestimate the intake of consumers being loyal to products ﬂavoured at the maximum use levels
reported).3 However, it is considered as a suitable tool to screen and prioritise the ﬂavouring
substances according to the need for reﬁned intake data (EFSA, 2004).
2.3.1. Estimated daily per capita intake (MSDI approach)
The intake estimation is based on the MSDI approach, which involves the acquisition of data on the
amounts used in food as ﬂavourings (SCF, 1999). These data are derived from surveys on annual
production volumes in Europe. These surveys were conducted in 1995 by the International
Organization of the Flavour Industry, in which ﬂavour manufacturers reported the total amount of each
ﬂavouring substance incorporated into food sold in the EU during the previous year (IOFI, 1995). The
intake approach does not consider the possible natural occurrence in food.
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is
consumed by 10% of the population (Eurostat, 1998).4 This is derived for candidate substances from
Table 2: Candidate substance reported to occur in food (TNO, 2015)
FL-no Name Quantitative data reported
13.117 2,5-Dimethyl-4-ethoxyfuran-3(2H)-one Up to 8 mg/kg in coffee(a)
13.119 2,5-Dimethylfuran-3(2H)-one 10.7 mg/kg in coffee(a)
FL-no: FLAVIS-number.
(a): The database refers to ‘coffee’ but it is not clear whether this reﬂects to coffee beans or to the beverage.
4 EU ﬁgure 375 million. This ﬁgure relates to EU population at the time for which production data are available, and is consistent
(comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available for the enlarged EU.
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estimates of annual volume of production provided by Industry and incorporates a correction factor of
0.6 to allow for incomplete reporting (60%) in the Industry surveys (SCF, 1999).
The total annual volume of production of the three candidate substances in the present FGE.313
from use as ﬂavouring substance in Europe has been reported to be approximately 25 kg (EFFA,
2004b, 2015).
On the basis of the annual volume of production reported for the candidate substances, the daily
per capita intakes have been estimated. The estimated daily per capita intake from use as a ﬂavouring
substance is 0.018 lg for 2,5-Dimethyl-4-ethoxyfuran-3(2H)-one [FL-no: 13.117]; 1.7 lg for 2,5-
dimethylfuran-3(2H)-one [FL-no: 13.119] and 1.3 lg for 4-Acetyl-2,5-dimethylfuran-3(2H)-one [FL-no:
13.175] (Table 4).
2.3.2. Intake estimated on the basis of the modiﬁed TAMDI (mTAMDI)
The method for calculation of modiﬁed Theoretical Added Maximum Daily Intake (mTAMDI) values
is based on the approach used by SCF up to 1995 (SCF, 1995).
The assumption is that a person may consume a certain amount of ﬂavoured foods and beverages
per day.
For the three candidate substances, information on food categories and normal and maximum use
levels5,6 was submitted by the Flavour Industry (EFFA, 2004b). The candidate substance is used in
ﬂavoured food products divided into the food categories outlined in Annex III of the Commission
Regulation (EC) No 1565/20003, as shown in Table 3. For the present calculation of mTAMDI, the
reported normal use levels were used. In the case where different use levels were reported for
different food categories, the highest reported normal use level was used.
Table 3: Use of the candidate substances
Food category Description Flavouring used
01.0 Dairy products, excluding products of category 2 Yes
02.0 Fats and oils, and fat emulsions (type water-in-oil) Yes
03.0 Edible ices, including sherbet and sorbet Yes
04.1 Processed fruits Yes
04.2 Processed vegetables, including mushrooms & fungi, roots & tubers,
pulses and legumes, and nuts & seeds
No
05.0 Confectionery Yes
06.0 Cereals and cereal products, including ﬂours & starches from roots &
tubers, pulses & legumes, excluding bakery
Yes
07.0 Bakery wares Yes
08.0 Meat and meat products, including poultry and game Yes
09.0 Fish and ﬁsh products, including molluscs, crustaceans and
echinoderms
Yes
10.0 Eggs and egg products No
11.0 Sweeteners, including honey No
12.0 Salts, spices, soups, sauces, salads, protein products, etc. Yes
13.0 Foodstuffs intended for particular nutritional uses Yes
14.1 Non-alcoholic (‘soft’) beverages, excluding dairy products No
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic
counterparts
Yes
15.0 Ready-to-eat savouries Yes
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) – foods
that could not be placed in categories 1–15
Yes
5 ‘Normal use’ is deﬁned as the average of reported usages and ‘maximum use’ is deﬁned as the 95th percentile of reported
usages (EFFA, 2002).
6 The normal and maximum use levels in different food categories3 have been extrapolated from ﬁgures derived from 12 model
ﬂavouring substances (EFFA, 2004).
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According to the Flavour Industry, the normal use levels for the candidate substance are in the
range of 1–5 mg/kg food, and the maximum use levels are in the range of 5–25 mg/kg (EFFA, 2004b)
(see Table D.3, Appendix C).
The mTAMDI value is 1,000 lg/person per day for each of the candidate substances from structural
class III.
For detailed information on use levels and intake estimations based on the mTAMDI approach, see
Section 5 and Appendix C.
3. Absorption, distribution, metabolism and elimination
In FGE.99Rev1, EFSA was in agreement with the Joint FAO/WHO Expert Committee on Food
Additives (JECFA) (JECFA, 2006, 63rd meeting, FAS 54) evaluation of the substances 4-hydroxy-2,5-
dimethyl-furan-3(2H)-one [FL-no: 13.010] and 2,5-dimethyl-4-methoxyfuran-3(2H)-one [FL-no: 13.089]
in taking them via the A-side of the Procedure. 4-Hydroxy-2,5-dimethyl-furan-3(2H)-one [FL-no:
13.010] is expected to form a glucuronic acid conjugate, and to be excreted via the urine. The ether
bond of 2,5-dimethyl-4-methoxyfuran-3(2H)-one [FL-no: 13.089] is expected to be readily cleaved.
The formed hydroxy-furanone can subsequently be conjugated with glucuronic acid and excreted in
the urine. In accordance with this, it is expected that the structurally similar candidate substance 2,5-
dimethyl-4-ethoxyfuran-3(2H)-one [FL-no:13.117], evaluated in this FGE.313, will be oxidised,
conjugated with glucuronic acid and excreted in the urine, and may be evaluated via the A-side of the
Procedure.
For the two candidate substances, 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] and 4-acetyl-2,5-
dimethylfuran-3(2H)-one [FL-no: 13.175], the metabolic fate is unclear, and accordingly it cannot be
anticipated that these substances will be metabolised to innocuous products.
4. Application of the Procedure for the safety evaluation of ﬂavouring
substances
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach.
Where the mTAMDI approach indicates that the intake of a ﬂavouring substance might exceed its
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure.
In these cases, the Panel requires more precise data on use and use levels. For comparison of the
intake estimations based on the MSDI approach and the mTAMDI approach, see Section 5.
For the safety evaluation of the three candidate substances from chemical group 13, the Procedure
as outlined in Appendix B was applied, based on the MSDI approach. The stepwise evaluation of the
substance is summarised in Table A.1.
Step 1
The three candidate substances are all classiﬁed according to the decision tree approach by Cramer
et al. (1978) into structural class III.
Step 2
One candidate substance 2,5-dimethyl-4-ethoxyfuran-3(2H)-one [FL-no:13.117] is expected to be
metabolised to innocuous products, and the evaluation proceeds via the A-side of the Procedure.
The two candidate substances, 2,5-dimethylfuran-3(2H)-one [FL-no:13.119] and 4-acetyl-2,5-
dimethylfuran-3(2H)-one [FL-no:13.175], cannot be anticipated to be metabolised to innocuous
products and thus the evaluation proceeds via the B-side of the Procedure scheme.
Step A3
The estimated daily per capita intake of the candidate substance 2,5-dimethyl-4-ethoxyfuran-3(2H)-
one [FL-no:13.117] is 0.018 lg which is below the threshold for its structural class of 90 lg/person per
day (class III). Accordingly, the substance is not expected to be of safety concern.
Step B3
The estimated daily per capita intake of the candidate substances, 2,5-dimethylfuran-3(2H)-one
[FL-no: 13.119] and 4-acetyl-2,5-dimethylfuran-3(2H)-one [FL-no: 13.175], are 1.7 and 1.3 lg,
respectively, which are below the threshold for their structural class of 90 lg/person per day (class
III). Accordingly, the evaluation of the substances proceeds to step B4 of the Procedure.
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Step B4
For one of these substances, 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119], a margin of safety could
be calculated based upon a BMDL05 of 0.94 mg/kg body weight (bw) per day for a decrease in total
white blood cell count derived from a 90-day oral gavage study (see Section 7 and Appendix F).
Compared to the MSDI of 1.7 lg/capita per day equal to 0.028 lg/kg bw or 0.000028 mg/kg bw per
day for this compound, this lower 95% conﬁdence limit (one-sided) for the BMD (BMDL) provides an
adequate margin of safety of 33 9 103.
Therefore, the Panel concluded that 2,5-dimethylfuran-3(2H)-one is not of safety concern based on
the MSDI approach.
For the candidate substance 4-acetyl-2,5-dimethylfuran-3(2H)-one [FL-no: 13.175], no adequate
study from which a no observed adverse effect level (NOAEL) or BMDL could be derived was available
neither for the candidate substance nor for a sufﬁciently structurally related substance. Therefore, the
Panel concluded that additional data are required for the candidate substance 4-acetyl-2,5-
dimethylfuran-3(2H)-one [FL-no: 13.175].
5. Comparison of the intake estimations based on the MSDI approach
and the mTAMDI approach
The estimated intake of each of the candidate substances assigned to structural class III, based on
the mTAMDI, is 1,000 lg/person per day, which is above the threshold of concern for structural class
III of 90 lg/person per day.
Thus, for all three candidate substance, further information is required. This would include more
reliable intake data and then, if required, additional toxicological data.
For comparison of the MSDI and mTAMDI values, see Table 4.
The estimated intake of each of the candidate substances assigned to structural class III, based on
the mTAMDI, is 1,000 lg/person per day, which is above the threshold of concern for structural class
III of 90 lg/person per day.
Thus, for all three candidate substance further information is required. This would include more
reliable intake data and then, if required, additional toxicological data.
6. Considerations of combined intakes from use as ﬂavouring
substances
Because of structural similarities of candidate and supporting substances, it can be anticipated that
many of the ﬂavourings are metabolised through the same metabolic pathways and that the
metabolites may affect the same target organs. Further, in case of combined exposure to structurally
related ﬂavourings, the pathways could be overloaded. Therefore, combined intake should be
considered. As ﬂavourings not included in this FGE may also be metabolised through the same
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed.
The total estimated combined daily per capita intake of structurally related ﬂavourings is estimated by
summing the MSDI for individual substances.
Table 4: Estimated intakes based on the MSDI approach and the mTAMDI approach
FL-no EU Register name
MSDI
(lg/capita per
day)
mTAMDI
(lg/person per
day)
Structural
class
Threshold of
concern
(lg/person per
day)
13.119 2,5-Dimethylfuran-3(2H)-one 1.7 1,000 Class III 90
13.117 2,5-Dimethyl-4-ethoxyfuran-
3(2H)-one
0.018 1,000 Class III 90
13.175 4-Acetyl-2,5-dimethylfuran-3
(2H)-one
1.3 1,000 Class III 90
MSDI: Maximised Survey-derived Daily Intake; mTAMDI: Modiﬁed Theoretical Added Maximum Daily Intake; FL-no: FLAVIS
number; EU: European Union.
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On the basis of the reported annual production volumes in Europe (EFFA, 2004b, 2015), the
estimated combined daily per capita intake as ﬂavourings of the three candidate substances assigned
to structural class III is approximately 3 lg, which does not exceed the threshold of concern for a
compound belonging to structural class III of 90 lg/person per day.
The three candidate substances are structurally related to ﬁve supporting substances (structural
class III) considered by EFSA in FGE.99 Revision 1 (EFSA CEF Panel, 2015b). Based on reported
production volumes, European per capita intakes (MSDI) could be estimated for all ﬁve supporting
substances.
The total combined intake of the candidate and supporting substances belonging to structural class
III is approximately 1,540 lg/capita per day, which exceeds the threshold of concern for a compound
belonging to structural class III of 90 lg/person per day. The main contribution to this MSDI originates
from three supporting substances, 4-hydroxy-2,5-dimethylfuran-3(2H)-one [FL-no: 13.010], ethyl-4-
hydroxy-5-methyl-3(2H)-furanone [FL-no: 13.084] and acetoxy-2,5-dimethylfuran-3(2H)-one [FL-no:
13.099] for which the estimated daily per capita intake is 1,520 lg, of which approximately 60%
comes from [FL-no: 13.010] for which a NOAEL of 200 mg/kg bw per day was determined in a chronic
toxicity study (Kelly and Bolte, 2003). This provides an adequate margin of safety for the combined
exposure of 8,000.
7. Toxicity
7.1. Acute toxicity
No data are available for the candidate substances.
7.2. Subacute, subchronic, chronic and carcinogenicity studies
7.2.1. 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119]
7.2.1.1. 14-day dietary range-ﬁnding study
In a preliminary palatability and range-ﬁnding study, 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119]
was administered to male and female CRL Sprague–Dawley® CD®IGS rats (5/sex per group) for
14 consecutive days in the diet at dietary concentrations of 3,000, 6,000 and 12,000 mg/kg for target
dose levels of 250, 500 and 1,000 mg/kg bw per day (Bauter, 2015a). Homogeneity analysis showed
that the substance was homogeneously distributed in the feed. Stability analysis was performed on
diets sampled on 0, 4, 7 and 10 days after preparation and revealed considerable loss of 2,5-
dimethylfuran-3(2H)-one, resulting in dietary levels that were 47.5%, 46.1% and 42.9% of the target
dietary concentrations on average over the course of the study. Based on the results of stability
analysis and on feed consumption data, the mean daily intake was calculated to be 125, 210 and
329 mg/kg bw per day, respectively, for males, and 138, 239 and 366 mg/kg bw per day, respectively,
for females, over the course of the study.
There were no mortalities during this study. Feed consumption was signiﬁcantly reduced over the
course of the study at all intake levels, and resulted in decreased overall body weights and body
weight gains in all treatment groups. Clinical observations included slightly thin appearance in one
high-dose female and reduced faecal volume in all high-dose animals, both considered to be
associated with reduced feed consumption. No other clinical observations were reported or any
abnormal macroscopic ﬁndings at scheduled necropsy attributable to administration of 2,5-
dimethylfuran-3(2H)-one.
Due to the observed instability in the feed matrix and lack of palatability, dietary administration of
2,5-dimethylfuran-3(2H)-one was not considered feasible for a longer duration study. The dose levels
for the 90-day follow-up study (see below) were based on the adjusted mean daily intakes for male
and female rats in the low-dose group of approximately 125 and 138 mg/kg bw per day in this 14-day
range-ﬁnding study, respectively (Bauter, 2015a).
7.2.1.2. 90-day oral gavage study
In an OECD Section 4 (part 408) compliant subchronic toxicity study, 2,5-dimethylfuran-3(2H)-one
[FL-no: 13.119] was administered to Sprague–Dawley Crl:CD (SD) IGS BR strain rats by oral gavage
(10/sex per dose) at dose levels of 15, 45 and 135 mg/kg bw per day for 90 days (Bauter, 2015b).
Administration of the test substance by oral gavage was selected in this study in the light of signiﬁcant
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instability in the feed and lack of palatability. Test suspensions were prepared daily, were kept on a stir
plate during dosing and were used within 2 h. Samples of the neat test substance were taken at the
beginning, middle and end of the study, and were found to be stable. Samples of the dosing
preparations were taken on days 1, 43 and 93 of the study to verify dosing concentrations, and were
found to be between 95.1% and 109.6% of the target concentrations of 0.3%, 0.9% and 2.7% of test
substance in vehicle (distilled water).
Animals were observed during daily handling, and individual detailed clinical observations were
made weekly. Very few observations have been recorded from the weekly detailed clinical
observations, and none of these give any indication of being related to dosage and/or length of
treatment. However, observations made during daily handling have been recorded that may give
reason to assume a dose–effect relationship. In particular, during daily handling, hypersalivation has
been recorded in the mid-dose and the high-dose groups, the ﬁrst occasions on day 8 of the study
and the last on day 72. Notations of hypersalivation in males and females of the high-dose group are
about four times more frequent than in the mid-dose group; 14 separate observations have been
made in the mid-dose group (in 6/10 males and in 4/10 females) and 57 separate observations in the
high-dose group (in 8/10 males and 7/10 females). Contrary to the observations during daily handling,
only two observations of hypersalivation have been made during the weekly individual detailed clinical
observations; both of these on day 8 of the study; one in a female of the mid-dose group and one in a
female of the high-dose group.
The Panel noted that most of the notations of salivation made during daily handling have been
made on days when the animals were not subject to detailed clinical observation. Ten of the daily
handling notations of salivation have been made on days when the animals indeed were also subjected
to detailed clinical observations, but for these 10 observations no recordings were mentioned in the
report of the detailed clinical observations. This might suggest that the salivation was of short duration
otherwise it is difﬁcult to explain this discrepancy. The study authors argued that as ﬁndings of
hypersalivation was resolved by day 72 and had no histopathological correlate, hypersalivation was not
an adverse effect. However, given that a dose–effect relationship exists for hypersalivation and no
hypersalivation was observed in the control and low-dose groups, this effect cannot be explained by
handing or gavage dosing and must be substance related. Therefore, the Panel decided not to
disregard this observation.
Changes in haematology parameters included statistically signiﬁcant (p < 0.05, Dunnett’s two-sided
or Dunnett’s non-parametric two-sided test) decreases in total white blood cell counts and neutrophils,
in males only, of the mid- and high-dose groups, with the decrease in white blood cell counts being
slightly more severe in the mid-dose group. Other statistically signiﬁcant changes included, decreased
absolute lymphocyte, eosinophil and basophil counts in males at mid-dose only. As the neutrophils are
part of the total white blood cell counts, the latter was submitted for BenchMark Dose (BMD) analysis.7
In the high-dose females, an increased absolute reticulocyte count was observed (28% up) but
without any other major changes in red blood cells or bone marrow cellularity, this observation in
females only is without biological relevance. There were no statistically signiﬁcant changes in
coagulation parameters.
Statistically signiﬁcant changes in clinical chemistry parameters included increases in alkaline
phosphatase (~ 28%) and total bilirubin (~ 40%) in high-dose group males and decreased aspartate
aminotransferase (~ 28%) in high-dose group females, which latter change has no toxicological
relevance. Changes reaching statistical signiﬁcance were observed in males only in some clinical
chemistry parameters (increased cholesterol, total protein, albumin, Ca, P, K and decreased Cl).
However, the latter changes were of limited magnitude without toxicological relevance, as was the
limited increase in alkaline phosphatase. Because the increase in plasma total bilirubin is more
indicative of liver damage than the small changes in circulating liver enzymes, plasma total bilirubin
was chosen for the BMDL calculation.
There were no changes in urine analysis parameters between treated and control animals.
Body weights, body weight gain, feed consumption and feed efﬁciency were overall comparable
between low-dose animals and control animals, as well as between mid-dose females and control.
Body weight and body weight gain were generally lower in mid- and high-dose males compared to
7 BMDL: lower 95% conﬁdence limit (one-sided) for the BMD. BMD is the dose which is associated with a predeﬁned risk level
(i.e. Benchmark response (BMR)). According to the guidance (EFSA Scientiﬁc Committee, 2009), the default BMR is an extra
risk of 10% in incidence (compared to the incidence in the control animals) for quantal response data or a change of 5% in
the population geometric mean for continuous response data.
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control, reaching statistical signiﬁcance for the study overall. High-dose females had lower body weight
and body weight gain compared to control, but did not reach statistical signiﬁcance. Feed consumption
was decreased in mid- and high-dose group males and feed efﬁciency was decreased in mid- and
high-dose males, reaching statistical signiﬁcance for the study overall.
In males, the relative liver weights (relative to body weight) were statistically signiﬁcantly increased
at all doses levels, whereas the relative kidney, testes and epididymides were only statistically
signiﬁcantly increased at the high dose. In females, only the relative liver weights (relative to body
weight) were statistically signiﬁcantly increased at the high-dose level. Increased ratios of kidney and
liver weights relative to brain weight were also reported at the 135 mg/kg bw per day dose level for
both males and females. Statistically signiﬁcant decreases in absolute organ weights were reported in
females for adrenal glands at the high dose, and brain at mid- and high doses, and in males, for brain
at high dose, heart at mid- and high doses, and spleen at mid dose. As these changes did not show a
dose response, or were not reﬂected in organ weights relative to body- and or brain weight, these
absolute organ weight changes were not considered of toxicological relevance. Relative organ weight
changes (to body weight) were considered for BMDL calculation.
No test substance-related macroscopic ﬁndings were found in the study. Animals from control and
high-dose groups were subject to full histopathological examinations, as were any gross lesions found
in animals from low- and mid-dose groups. No microscopic ﬁndings related to the test substance were
identiﬁed.
The Panel decided to derive a BMDL from this study, rather than the NOAEL, in line with the
Opinion of the EFSA Scientiﬁc Committee (EFSA Scientiﬁc Committee, 2009). Details of the BMDL
estimation have been presented in Appendix F. The following observations were the most relevant:
hypersalivation in the mid- and high-dose groups, changes in white blood cell counts, changes in body
weight changes in relative organ weight (liver, kidneys, epididymides and testes) and changes in
plasma total bilirubin. For the various toxicity parameters analysed, the BMDL05 of 0.94 mg/kg bw per
day for a 5% decrease in total white blood cell count was the lowest value obtained. This BMDL is
used for the evaluation of 2,5-dimethylfuran-3(2H)-one.
Toxicity data are summarised in Table F.1.
7.3. Developmental/reproductive toxicity studies
No data on developmental toxicity and reproductive toxicity are available for the candidate
substances.
7.4. Genotoxicity
2,5-Dimethylfuran-3(2H)-one [FL-no: 13.119] was evaluated in FGE.220Rev2 (EFSA CEF Panel,
2013) and 4-acetyl-2,5-dimethylfuran-3(2H)-one [FL-no: 13.175] was evaluated in FGE.220Rev3 (EFSA
CEF Panel, 2015a) with respect to genotoxicity.
They were both tested in Salmonella Typhimurium strains TA98, TA100, TA1535, TA1537 and
TA102, both in the absence and presence of S9-mix (Sokolowski, 2007; Bowen, 2011). Both candidate
substances were also tested in an in vitro micronucleus assay in human peripheral blood lymphocytes,
with and without metabolic activation, for their ability to induce chromosomal damage or aneuploidy
(Lloyd, 2011, 2012, 2014). The two candidate substances [FL-no: 13.119 and 13.175] did not induce
mutations and did not induce increased levels of micronuclei in these valid studies.
The Panel therefore concluded that the two candidate substances for which genotoxicity data were
submitted (2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] and 4-acetyl-2,5-dimethylfuran-3(2H)-one
[FL-no: 13.175]) do not give rise to concern with respect to genotoxicity. The same conclusion applies
to 2,5-dimethyl-4-ethoxyfuran-3(2H)-one [FL-no: 13.117], which is structurally related with respect to
the a,b-unsaturated carbonyl moiety. Therefore, these three substances can be evaluated using the
Procedure. Genotoxicity data are summarised in Table F.2.
8. Conclusion
The FGE.313 deals with the evaluation of three a,b-unsaturated 3(2H)-furanone derivatives from
chemical group 13. These three candidate substances are 2,5-dimethyl-4-ethoxyfuran-3(2H)-one
[FL-no: 13.117], 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] and 4-acetyl-2,5-dimethylfuran-3(2H)-
one [FL-no: 13.175].
Flavouring Group Evaluation 313
www.efsa.europa.eu/efsajournal 14 EFSA Journal 2016;14(7):4531
All three substances possess one chiral centre and their stereoisomeric composition has been
speciﬁed.
The three candidate substances were assigned to structural class III, according to the decision tree
approach presented by Cramer et al. (1978).
[FL-no: 13.117 and 13.119] have been reported to occur naturally in food.
According to the default MSDI approach, the candidate substances in this group have intakes in
Europe from 0.018 to 1.7 lg/capita per day. For all the candidate substances, this is below the
threshold of concern value for structural class III (90 lg/person per day). On the basis of the reported
annual production volumes in Europe (EFFA, 2004b), the estimated combined daily per capita intake as
ﬂavourings of the three candidate substances assigned to structural class III is approximately 3 lg,
which does not exceed the threshold of concern for a compound belonging to structural class III of
90 lg/person per day.
The Panel concluded that the two candidate substances for which genotoxicity data were submitted
(2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] and 4-acetyl-2,5-dimethylfuran-3(2H)-one [FL-no:
13.175]) do not give rise to concern with respect to genotoxicity. The same conclusion applies to 2,5-
dimethyl-4-ethoxyfuran-3(2H)-one [FL-no: 13.117], which is structurally related with respect to the
a,b-unsaturated carbonyl moiety. Therefore, these three substances can be evaluated using the
Procedure.
The candidate substance [FL-no: 13.117] is expected to be metabolised to innocuous products.
Therefore, [FL-no: 13.117] was evaluated via the A-side of the Procedure. [FL-no: 13.119 and 13.175]
cannot be anticipated to be metabolised to innocuous products. Consequently, these two substances
were evaluated via the B-side of the Procedure.
It is considered that the two candidate substances, 2,5-dimethyl-4-ethoxyfuran-3(2H)-one [FL-no:
13.117] and 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119], evaluated through the Procedure would not
give rise to safety concerns at the estimated levels of intake arising from their use as ﬂavouring
substances on the basis of the default MSDI approach. Additional toxicity data are required for
4-acetyl-2,5-dimethylfuran-3(2H)-one [FL-no: 13.175].
In order to determine whether the conclusion for the candidate substances can be applied to the
materials of commerce, it is necessary to consider the available speciﬁcations.
Adequate speciﬁcations including complete purity criteria and identity for the material of commerce
have been provided for the ﬂavouring substances.
The estimated intake based on the mTAMDI approach is 1,000 lg/person per day for each of the
candidate substances from structural class III, which is above the threshold of concern for structural
class III of 90 lg/person per day. The Panel concluded that for 2,5-dimethyl-4-ethoxyfuran-3(2H)-one
[FL-no: 13.117], 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] and 4-acetyl-2,5-dimethylfuran-3(2H)-
one [FL-no: 13.175] for which the mTAMDIs are above the thresholds for their structural class, more
reliable exposure data are required. On the basis of such additional data, these ﬂavouring substances
should be reconsidered using the Procedure. Subsequently, additional toxicity data might become
necessary. For the candidate substance [FL-no: 13.175], toxicity data are required.
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Abbreviations
BMD BenchMark Dose
BMDL lower 95% conﬁdence limit (one-sided) for the BMD
BMDU upper 95% conﬁdence limit (one-sided) for the BMD
BMR Benchmark response
bw body weight
CAS Chemical Abstract Service
CEF EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
Chemical
CoE Council of Europe
EFFA European Flavour and Fragrance Association
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
GLP good laboratory practice
GUI graphical user interface
ID identity
IOFI International Organization of the Flavour Industry
IR infrared spectroscopy
JECFA The Joint FAO/WHO Expert Committee on Food Additives
MNBN micronucleated binucleated cells
MS mass spectrometry
MSDI Maximised Survey-derived Daily Intake
mTAMDI Modiﬁed Theoretical Added Maximum Daily Intake
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NTP National Toxicology Program
OECD Organisation for Economic Co-operation and Development
SCF Scientiﬁc Committee on Food
TAMDI Theoretical Added Maximum Daily Intake
WBC white blood cell
WHO World Health Organization
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Appendix A – Summary of the safety evaluation
Table A.1: Summary of the safety evaluation for the substances in FGE.313 applying the Procedure
FL-no
EU Register
name
Structural
formula
MSDI(a)
(lg/capita
per day)
Class(b)
Evaluation
procedure
path(c)
Outcome on
the named
compound
[(d) or (e)]
Outcome on
the material
of commerce
[(f), (g) or (h)]
Evaluation
remarks
13.119 2,5-
Dimethylfuran-3
(2H)-one
1.7 Class III
B3: Intake below
threshold,
B4: Adequate
NOAEL exists
d F Evaluated in
FGE.220Rev2,
genotoxicity
concern could be
ruled out
13.117 2,5-Dimethyl-4-
ethoxyfuran-3
(2H)-one
0.018 Class III
A3: Intake below
threshold
d F Evaluated in
FGE.220Rev3,
genotoxicity
concern could be
ruled out
13.175 4-Acetyl-2,5-
dimethylfuran-3
(2H)-one
1.3 Class III
B3: Intake below
threshold,
B4: Toxicity data
are required
d F Evaluated in
FGE.220Rev3,
genotoxicity
concern could be
ruled out
FGE: Flavouring Group Evaluation; FL-no: FLAVIS number; MSDI: Maximised Survey-derived Daily Intake; NOAEL: No Observed Adverse Effect
Level.
(a): EU MSDI: Amount added to food as ﬂavour in (kg/year) 9 10E9/(0.1 9 population in Europe (= 375 9 10E6) 9 0.6 9 365) = lg/capita per day.
(b): Thresholds of concern: Class I = 1,800 lg/person per day, Class II = 540 lg/person per day, Class III = 90 lg/person per day.
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
(d): No safety concern based on intake calculated by the MSDI approach of the named compound.
(e): Data must be available on the substance or closely related substances to perform a safety evaluation.
(f): No safety concern at the estimated level of intake of the material of commerce meeting the speciﬁcation requirement (based on intake
calculated by the MSDI approach).
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on
the purity of the material of commerce and/or information on stereoisomerism.
(h): No conclusion can be drawn due to lack of information on the purity of the material of commerce.
Table A.2: Summary of supporting substances evaluated in FGE.99 (EFSA CEF Panel, 2012)
FL-no EU Register name
Structural
formula
FEMA no
CoE no
CAS no
JECFA no
Speciﬁcation
available
MSDI (EU)(a)
(lg/capita per
day)
SCF status(b)
JECFA status(c)
CoE status(d)
13.010 4-Hydroxy-2,5-
dimethyl-furan-3
(2H)-one
3174
536
3658-77-3
1446
JECFA
speciﬁcation
(JECFA, 2005)
960 No safety
concern (JECFA,
2005)
Category B (CoE,
1992)
13.084 2-Ethyl-4-hydroxy-5-
methyl-3(2H)-
furanone
3623
27538-09-6(e)
1449
JECFA
speciﬁcation
(JECFA, 2005)
160 No safety
concern (JECFA,
2005)
13.085 4-Hydroxy-5-
methylfuran-3(2H)-
one
3635
11785
19322-27-1
1450
JECFA
speciﬁcation
(JECFA, 2005)
5.6 No safety
concern (JECFA,
2005)
13.089 2,5-Dimethyl-4-
methoxyfuran-3(2H)-
one
3664
4077-47-8
1451
JECFA
speciﬁcation
(JECFA, 2005)
19 No safety
concern (JECFA,
2005)
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FL-no EU Register name
Structural
formula
FEMA no
CoE no
CAS no
JECFA no
Speciﬁcation
available
MSDI (EU)(a)
(lg/capita per
day)
SCF status(b)
JECFA status(c)
CoE status(d)
13.099 4-Acetoxy-2,5-
dimethylfuran-3(2H)-
one
3797
4166-20-5
1456
JECFA
speciﬁcation
(JECFA, 2005)
400 No safety
concern (JECFA,
2005)
13.176 Furaneyl butyrate 3970 1519
JECFA
speciﬁcation
(JECFA, 2006)
12 No evaluation
(JECFA, 2009)
FL-no: FLAVIS-number; EU: European Union; FEMA: Flavor and Extract Manufacturers Association number; CoE: Council of
Europe number; CAS: Chemical Abstract Service number; JECFA: The Joint FAO/WHO Expert Committee on Food Additives
number; MSDI: Maximised Survey-derived Daily Intake; SCF: Scientiﬁc Committee on Food.
(a): EU MSDI: Amount added to food as ﬂavouring substance in (kg/year) 9 10E9/(0.1 9 population in
Europe (= 375 9 10E6) 9 0.6 9 365) = lg/capita per day.
(b): Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufﬁcient data to provide
assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity.
(c): No safety concern at estimated levels of intake.
(d): Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used
provisionally in foodstuffs.
(e): CASrn in the Register to be changed to 27538-10-9.
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Appendix B – Procedure for the safety evaluation
The approach for a safety evaluation of chemically deﬁned ﬂavouring substances as referred to in
Commission Regulation (EC) No 1565/20003, named the ‘Procedure’, is shown in schematic form in
Figure C.1. The Procedure is based on the Opinion of the Scientiﬁc Committee on Food expressed on
2 December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995,
1996, 1997, 1999).
The Procedure is a stepwise approach that integrates information on intake from current uses,
structure–activity relationships, metabolism and, when needed, toxicity. One of the key elements in the
Procedure is the subdivision of ﬂavourings into three structural classes (I, II and III) for which
thresholds of concern (human exposure thresholds) have been speciﬁed. Exposures below these
thresholds are not considered to present a safety concern.
Class I contains ﬂavourings that have simple chemical structures and efﬁcient modes of
metabolism, which would suggest a low order of oral toxicity. Class II contains ﬂavourings that have
structural features that are less innocuous, but are not suggestive of toxicity. Class III comprises
ﬂavourings that have structural features that permit no strong initial presumption of safety, or may
even suggest signiﬁcant toxicity (Cramer et al., 1978). The thresholds of concern for these structural
classes of 1,800, 540 or 90 lg/person per day, respectively, are derived from a large database
containing data on subchronic and chronic animal studies (JECFA, 1996).
In Step 1 of the Procedure, the ﬂavourings are assigned to one of the structural classes. The
further steps address the following questions:
• Can the ﬂavourings be predicted to be metabolised to innocuous products8 (Step 2)?
• Do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)?
• Are the ﬂavourings or their metabolites endogenous9 (Step A4)?
• Does a NOAEL exist on the ﬂavourings or on structurally related substances (Step A5 and B4)?
In addition to the data provided for the ﬂavouring substances to be evaluated (candidate
substances), toxicological background information available for compounds structurally related to the
candidate substances is considered (supporting substances), in order to assure that these data are
consistent with the results obtained after application of the Procedure.
The Procedure is not to be applied to ﬂavourings with existing unresolved problems of toxicity.
Therefore, the right is reserved to use alternative approaches if data on speciﬁc ﬂavourings warranted
such actions.
8 ‘Innocuous metabolic products’: Products that are known or readily predicted to be harmless to humans at the estimated
intakes of the ﬂavouring agent (JECFA, 1997).
9 ‘Endogenous substances’: Intermediary metabolites normally present in human tissues and ﬂuids, whether free or conjugated;
hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997).
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Appendix C – Procedure for safety evaluation of chemically deﬁned
ﬂavouring substances
Figure C.1: Procedure for safety evaluation of chemically deﬁned ﬂavouring substances
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Appendix D – Use levels/mTAMDI
D.1. Normal and maximum use levels
For each of the 18 Food categories (Table A.2) in which the candidate substances are used, Flavour
Industry reports a ‘normal use level’ and a ‘maximum use level’.3 According to the Industry, the
‘normal use’ is deﬁned as the average of reported usages and ‘maximum use’ is deﬁned as the 95th
percentile of reported usages (EFFA, 2002). The normal and maximum use levels in different food
categories have been extrapolated from ﬁgures derived from 12 model ﬂavouring substances (EFFA,
2004a).
The ‘normal and maximum use levels’ are provided by Industry for the candidate substances in the
present ﬂavouring group (Table D.1).
D.2. mTAMDI calculations
The method for calculation of modiﬁed Theoretical Added Maximum Daily Intake (mTAMDI) values is
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may
consume the amount of ﬂavourable foods and beverages listed in Table D.1. These consumption
estimates are then multiplied by the reported use levels in the different food categories and summed up.
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as
outlined in Commission Regulation (EC) No 1565/2000 and reported by the Flavour Industry in the
following way (see Table D.3):
• Beverages (SCF, 1995) correspond to food category 14.1
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13 and/or 16]
• Exception a (SCF, 1995) corresponds to food category 5 and 11
• Exception b (SCF, 1995) corresponds to food category 15
• Exception c (SCF, 1995) corresponds to food category 14.2
• Exception d (SCF, 1995) corresponds to food category 12
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum.
Table D.1: Food categories according to Commission Regulation (EC) No 1565/2000
Food category Description
01.0 Dairy products, excluding products of category 02.0
02.0 Fats and oils, and fat emulsions (type water-in-oil)
03.0 Edible ices, including sherbet and sorbet
04.1 Processed fruit
04.2 Processed vegetables (including mushrooms & fungi, roots & tubers, pulses and
legumes), and nuts & seeds
05.0 Confectionery
06.0 Cereals and cereal products, including ﬂours & starches from roots & tubers,
pulses & legumes, excluding bakery
07.0 Bakery wares
08.0 Meat and meat products, including poultry and game
09.0 Fish and ﬁsh products, including molluscs, crustaceans and echinoderms
10.0 Eggs and egg products
11.0 Sweeteners, including honey
12.0 Salts, spices, soups, sauces, salads, protein products, etc.
13.0 Foodstuffs intended for particular nutritional uses
14.1 Non-alcoholic (‘soft’) beverages, excluding dairy products
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic counterparts
15.0 Ready-to-eat savouries
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) – foods that could not
be placed in categories 01.0–15.0
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The mTAMDI value (see Table D.2) is presented for the ﬂavouring substances in the present
ﬂavouring group (EFFA, 2004b). The mTAMDI value is only given for the highest reported normal use
levels.
Table D.2: Estimated amount of ﬂavourable foods, beverages and exceptions assumed to be
consumed per person per day (SCF, 1995)
Class of product category Intake estimate (g/day)
Beverages (non-alcoholic) 324.0
Foods 133.4
Exception a: Candy, confectionery 27.0
Exception b: Condiments, seasonings 20.0
Exception c: Alcoholic beverages 20.0
Exception d: Soups, savouries 20.0
Exception e: Others, e.g. chewing gum 2.0 (chewing gum)
Table D.3: Estimated intakes based on the mTAMDI approach
FL-no EU Register name
mTAMDI
(lg/person
per day)
Structural
class
Threshold of concern
(lg/person per day)
13.119 2,5-Dimethylfuran-3(2H)-one 1,000 Class III 90
13.117 2,5-Dimethyl-4-ethoxyfuran-3(2H)-one 1,000 Class III 90
13.175 4-Acetyl-2,5-dimethylfuran-3(2H)-one 1,000 Class III 90
FL-no: FLAVIS number; EU: European Union; mTAMDI: Modiﬁed Theoretical Added Maximum Daily Intake.
Table D.4: Normal and maximum use levels (mg/kg) for the candidate substances in FGE.313 (EFFA,
2004b)
FL-no
Food categories
Normal use levels (mg/kg)
Maximum use levels (mg/kg)
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0
13.117 3 2 3 2 – 4 2 5 1 1 – – 2 3 – 4 5 2
15 10 15 10 – 20 10 25 5 5 – – 10 15 – 20 25 10
13.119 3 2 3 2 – 4 2 5 1 1 – – 2 3 – 4 5 2
15 10 15 10 – 20 10 25 5 5 – – 10 15 – 20 25 10
13.175 3 2 3 2 – 4 2 5 1 1 – – 2 3 – 4 5 2
15 10 15 10 – 20 10 25 5 5 – – 10 15 – 20 25 10
FL-no: FLAVIS number.
Table D.5: Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000
into the seven SCF food categories used for TAMDI calculation
Food categories according to Commission Regulation
(EC) No 1565/2000
Distribution of the seven SCF food
categoriesKey
Food category Food Beverages Exceptions
01.0 Dairy products, excluding products of category 02.0 Food
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food
03.0 Edible ices, including sherbet and sorbet Food
04.1 Processed fruit Food
04.2 Processed vegetables (including mushrooms & fungi, roots &
tubers, pulses and legumes), and nuts & seeds
Food
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Food categories according to Commission Regulation
(EC) No 1565/2000
Distribution of the seven SCF food
categoriesKey
Food category Food Beverages Exceptions
05.0 Confectionery Exception a
06.0 Cereals and cereal products, including ﬂours & starches from
roots & tubers, pulses & legumes, excluding bakery
Food
07.0 Bakery wares Food
08.0 Meat and meat products, including poultry and game Food
09.0 Fish and ﬁsh products, including molluscs, crustaceans and
echinoderms
Food
10.0 Eggs and egg products Food
11.0 Sweeteners, including honey Exception a
12.0 Salts, spices, soups, sauces, salads, protein products, etc. Exception d
13.0 Foodstuffs intended for particular nutritional uses Food
14.1 Non-alcoholic (‘soft’) beverages, excl. dairy products Beverages
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic
counterparts
Exception c
15.0 Ready-to-eat savouries Exception b
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) –
foods that could not be placed in categories 01.0–15.0
Food
SCF: Scientiﬁc Committee on Food; TAMDI: Theoretical Added Maximum Daily Intake.
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Appendix E – Absorption, distribution, metabolism and elimination
According to JECFA (2009), data on furan-substituted aliphatic hydrocarbons, alcohols, aldehydes,
ketones, carboxylic acids, and related esters, sulﬁdes, disulﬁdes and ethers with an oxygenated alkyl
substituent indicate that the furyl derivatives in this group are rapidly absorbed, metabolised and
excreted from animals.
In FGE.99Rev1, EFSA was in agreement with the JECFA (JECFA, 2006, 63rd meeting, FAS 54)
evaluation of the substances, 4-hydroxy-2,5-dimethyl-furan-3(2H)-one [FL-no: 13.010] and 2,5-
dimethyl-4-methoxyfuran-3(2H)-one [FL-no: 13.089], in taking them via the A-side of the Procedure.
4-Hydroxy-2,5-dimethyl-furan-3(2H)-one [FL-no: 13.010] is expected to form a glucuronic acid
conjugate, and to be excreted via the urine. The ether bond of 2,5-dimethyl-4-methoxyfuran-3(2H)-
one [FL-no: 13.089] is expected to be readily cleaved. The formed hydroxy-furanone can subsequently
be conjugated with glucuronic acid and excreted in the urine. In accordance with this, it is expected
that the structurally similar candidate substance, 2,5-dimethyl-4-ethoxyfuran-3(2H)-one [FL-no:13.117],
evaluated in this FGE.313, will be oxidised, conjugated with glucuronic acid and excreted in the urine, and
may be evaluated via the A-side of the Procedure.
For the two candidate substances, 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] and 4-acetyl-2,
5-dimethylfuran-3(2H)-one [FL-no: 13.175], the metabolic fate is unclear, and accordingly, it cannot be
anticipated that these substances will be metabolised to innocuous products.
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Appendix F – Toxicity
Table F.1: Toxicity data considered by the Panel in FGE.313
Chemical name
[FL-no:]
Species;
sex
no./group
Route
Doses (mg/kg
bw per day)
Duration
(days)
NOAEL
(mg/kg
bw per
day)
References Comments
2,5-Dimethylfuran-
3(2H)-one [13.119]
Rats; M,F
3/6
Diet 0, 125, 210, 329
(M) and 0, 138,
239, 366 (F)
14 Bauter
(2015a)
Dose-range ﬁnding
study
Rats; M,F
3/20
Gavage 15, 45, 135 90 15 Bauter
(2015b)
NOAEL was
suggested by the
author of the study
report
The Panel
calculated a BMDL05
of 0.94 mg/kg bw
per day for this
study
FGE: Flavouring Group Evaluation; FL-no: FLAVIS number; bw: body weight; NOAEL: No Observed Adverse Effect Level.
Table F.2: Genotoxicity data (in vitro) considered by the Panel in FGE.220Rev2 (EFSA CEF Panel, 2013) and FGE.220Rev3
(EFSA CEF Panel, 2015a)
Chemical name
[FL-no]
Test system Test object Dose
Reported
result
Reference Comments
2,5-
Dimethylfuran-3
(2H)-one
[13.119]
Reverse
mutation
Salmonella
Typhimurium
TA98, TA100,
TA102, TA1535
and TA1537
3–5,000 lg/plate(a),(b) Negative Sokolowski
(2007)
All strains were negative.
Study design complied with
current GLP and OECD
recommendations.
Acceptable top
concentration was achievedS. Typhimurium
TA98, TA100,
TA102, TA1535
and TA1537
33–5,000 lg/plate(a),(c) Negative
Micronucleus
Assay
Human peripheral
blood lymphocytes
900–1,120 lg/mL(a),(f)
900–1,120 lg/mL(d),(g)
Negative Lloyd
(2011)
The MNBN cell frequencies
in all treated cultures fell
within the normal range.
Complies with draft OECD
Guideline 487 and GLP
recommendations
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Chemical name
[FL-no]
Test system Test object Dose
Reported
result
Reference Comments
4-Acetyl-2,5-
dimethylfuran-3
(2H)-one
[13.175]
Reverse
Mutation
S. Typhimurium
TA98, TA100,
TA102, TA1535
and TA1537
0.32–5,000 lg/plate(a),(b) Negative (Bowen,
2011)
Evidence of toxicity was
observed at 5,000 lg/plate
in all strains in the absence
and presence of S9. Study
design complied with
current GLP and OECD
recommendations
78.13–5,000 lg/plate(b),(d)
78.13–5,000 lg/plate(c),(d)
Negative
Micronucleus
Assay
Human peripheral
blood lymphocytes
1,000–1,542 lg/mL(a),(f)
400–900 lg/mL(d),(g)
Negative Lloyd
(2012)
Study in compliance with
GLP and OECD
recommendations. Statistical
signiﬁcant increase, dose-
related, in the presence of
S9-mix at all three
concentrations in a ﬁrst
experiment. Lower statistical
signiﬁcance at the two
highest concentrations in an
enlarged scoring, carried out
with an unjustiﬁed
approach. Mean MNBN cell
frequencies fell within the
historical control range with
exception of a single
replicate (see main text)
1,000, 1,250 and
1,542 lg/mL(e),(f)
Negative Lloyd
(2014)
Follow-up study in
compliance with GLP and
OECD recommendations.
Statistically signiﬁcant
increase (p ≤ 0.05) in the
mean frequency of
micronuclei was reported
only at the lowest of the
three concentrations tested
(1,000 lg/mL) but remained
well within the normal
historical control range
values (0.1–0.9%) for both
replicate cultures
FGE: Flavouring Group Evaluation; FL-no: FLAVIS number; GLP: Good Laboratory Practice; OECD: Organisation for Economic Co-operation and
Development; MNBN: micronucleated binucleated cells.
(a): With and without S9 metabolic activation.
(b): Plate incorporation method.
(c): Preincubation method.
(d): Without S9 metabolic activation.
(e): With S9 metabolic activation.
(f): 3-h incubation with 21-h recovery period.
(g): 24-h incubation with no recovery period.
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Appendix G – Dose–response modelling for 2,5-dimethylfuran-3(2H)-one
[FL-no: 13.119]
In compliance with the Opinion of the EFSA Scientiﬁc Committee on the use of the Benchmark dose
(BMD)7 approach in Risk Assessment (EFSA Scientiﬁc Committee, 2009), the results obtained in the
subchronic study with 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119] (Bauter, 2015b) have been
submitted to statistical dose–response modelling. This study has been summarised in Section 7.2 of
the main document, where it was explained that the following observations were used for the
calculation of the BMDL from this study: hypersalivation, body weight changes, changes in total white
blood cell count (WBC), relative liver weight changes, relative kidney weight changes, changes in
relative weight of testes and epididymis, and changes in plasma total bilirubin.
For all modelling, the statistical package PROAST (version 61.5) has been used in graphical
user interface mode (GUI-mode). This package is available via: http://www.rivm.nl/en/foodnutrition
andwater/foodsafety/proast.jsp; the version mentioned can be requested directly from the authors.
Using this statistical package, 95% lower conﬁdence limit (single-sided) of the BMDLs were calculated
(see EFSA Scientiﬁc Committee, 2009) for the various effects. For each evaluation, all statistical models
available in PROAST (i.e. the ‘EPA-models’ plus the Exponential and Hill families of models) were used.
The dose–response modelling was carried out using means, SDs and group sizes as provided in the
study report. The data used have been presented in Table G.1.
The evaluations were carried out in GUI-mode with the following settings:
• Benchmark response: According to the Guidance (EFSA Scientiﬁc Committee, 2009), the
default Benchmark response is an extra risk of 10% in incidence (compared to the incidence in
the control animals) for quantal response data or a change of 5% in the population geometric
mean for continuous response data. However, the Panel notes that these default values might
be more conservative than necessary for individual toxicity parameters.
• No restrictions for model parameters to limit e.g. steepness of the ﬁtted dose–response curves
(default option; cannot be modiﬁed in GUI-mode).
• Sex was used as a covariate.
For all evaluations, the following criteria were used to decide on acceptability of modelling output:
• p-value for goodness of ﬁt: 0.05.
• For continuous variables (i.e. all except hypersalivation), the Exponential and Hill nested model
families were used. Dose–response modelling for hypersalivation (quantal data) was carried
out using the EPA-models as well as the Exponential and Hill model families.
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G.1. Quantal responses: hypersalivation
The results of the BMD analysis for hypersalivation have been presented in Table G.2.
From Table G.2, it can be concluded that all models, except the logistic model gave an acceptable
ﬁt. As none of the models is a priori preferable above one of the others, the BMDL, which can be
selected from this table, is 4.89 mg/kg bw per day from the EPA Weibull model. This BMDL is the
lowest BMDL calculated. The BMDU for this parameter is obtained from the Exponential model (m4).
Note that the 90% conﬁdence intervals (two-sided) around the BMDs are rather small, and that also
the differences between the various models are relatively limited. A graphical representation of the
modelled dose–response curve is given in Figure G.1. Note that in this plot, the maximal observable
incidence of the effect is normalised to 1, which would represent response in all animals of the group.
Table G.2: Results of a BMD analysis of the data from Bauter (2015b): occurrence of
hypersalivation in animals dosed via gavage with 2,5-dimethylfuran-3(2H)-one
Model n.par loglik Accepted BMDL(a) BMDU(a) BMD(a) sens.subgr
null 1 50.45
full 8 25.01
two.stage- 3 29.37 Yes 6.96 22.3 10.1 –
log.logist- 3 28.07 Yes 8.31 27.0 17.3 –
Weibull- 3 29.12 Yes 4.89 24.8 13.6 –
log.prob- 3 27.81 Yes 9.62 28.1 18.6 –
gamma- 3 28.92 Yes 5.32 27.1 15.7 –
logistic- 2 33.71 No 28.5 –
LVM_Exp: m4- 3 25.06 Yes 18.40 33.3 28.1 –
LVM_Hill: m2- 2 28.00 Yes 10.60 21.9 16.0 –
BMDL: lower 95% conﬁdence limit (one-sided) for the BMD; BMDU: upper 95% conﬁdence limit (one-sided) for the BMD;
BMD: BenchMark Dose.
(a): BMD, BMDL and BMDU are in mg/kg bw per day; 5 days/week.
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Figure G.1: Weibull dose–response analysis for incidence of hypersalivation as reported in a 90-day
oral toxicity study with 2,5-dimethylfuran-3(2H)-one [FL-no:13.119] (Bauter, 2015b).
Lower squares are the incidences observed in the females, upper squares are the
incidences observed in the males
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G.2. Continuous responses
All other responses mentioned above were continuous responses, for which group means, standard
deviations and groups size were used as input parameters for the BMDL calculations (see Table G.3).
For continuous responses, only the Hill and Exponential nested model families are applicable. In GUI-
mode, PROAST has two options for dose–response modelling: either selection of the minimum model
or selection of the maximum model. The minimum model is the model that uses the smallest number
of model parameters that result in a statistically acceptable description of the empirical data. Adding
more model parameters would not statistically improve the quality of the ﬁtted dose–response curve,
in the light of the degrees of freedom available. The maximum model always provides estimates for all
model parameters irrespective of whether a higher number of model parameters actually improves the
quality of the modelling. This is a deviation from the approach described in the EFSA opinion of 2009.
The current view is that the use of the maximum model takes a better account of the uncertainty in
the dose–response, and therefore should be preferable to the minimal model approach (Slob and
Setzer, 2014; EFSA Scientiﬁc Committee, 2016). For the sake of completeness, the BMDLs from both
approaches have been provided in Table G.3. Note that the BMDL and BMDU values may come from
different models, even within one parameter (as is the case for hypersalivation).
For all parameters, for both model families acceptable ﬁts were obtained. For almost all
parameters, the 90% conﬁdence interval (two-sided) around the BMD (BMDL–BMDU) was not
extremely wide, (usually less than a factor of 10). However, for the total white blood cell counts, in the
females no upper bound estimate for the BMD (BMDU) could be calculated. Nevertheless, the more
relevant lower bound estimate (BMDL) could be estimated. As can be seen in the main text, the
female response for this parameter was less pronounced than in the males, which is also reﬂected in
the results of the dose–response modelling.
The ﬁgure below (Figure G.2) gives the graphical representation of the ﬁtted dose–response curves
for the total white blood cell counts (upper panel; minimal model). The lower panel gives the dose–
response curves for plasma total bilirubin (maximum model).
Table G.3: Overview of BMDL and BMDU values for 2,5-dimethylfuran-3(2H)-one [FL-no: 13.119].
The values are for continuous parameters and obtained with either Hill or Exponential
nested model families
Parameter Direction of
change
Minimal model Maximal model
BMDL05 BMDU05 BMDL05 BMDU05
Body weight changes Decrease F+M: 18.77 43.11 F+M: 19.46 42.95
Total white blood cell count (WBC)
changes
Decrease F: 8.07 Inf F: 36.28 Inf
M: 0.94 9.22 M: 4.54 35.60
Relative liver weight changes Increase F: 40.06 93.40 F: 27.07 94.46
M: 21.38 33.64 M: 7.30 54.83
Relative kidney weight changes Increase F: 48.42 117.10 F: 53.80 134.46
M: 27.24 42.65 M: 25.27 62.07
Relative testes weight of changes Increase 28.80 87.43 18.60 91.08
Relative epididymis weight changes Increase 26.59 72.70 10.80 53.49
Plasma total bilirubin changes Increase F+M: 18.56 36.23 F: 11.16 132.29
M: 3.16 45.68
BMDL: lower 95% conﬁdence limit (one-sided) for the BMD; BMDU: upper 95% conﬁdence limit (one-sided) for the BMD.
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When the maximum model is used, the lowest BMDL (3.16 mg/kg bw per day) is connected to
increased plasma total bilirubin.
According to the EFSA guidance (EFSA Scientiﬁc Committee, 2009), the minimal model is the one
to be used for BMDL calculations. As the dose–response modelling for the total white blood cell counts
in the males resulted in the lowest BMDL of 0.94 mg/kg bw per day, this BMDL will be used for the
assessment of [FL-no: 13.119].
Figure G.2: Dose–response modelling for 2,5-dimethylfunan-3(2H)-one [FL-no: 13.119]. Upper Panel:
total white blood cell counts (minimal model). Lower panel: plasma total bilirubin
(maximum model). The black curves represent the females, the red curves represent the
males
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